New drug cocktail shows promise against rare blood cancer
NCT ID NCT05051891
First seen Apr 09, 2026 · Last updated Jun 20, 2026 · Updated 12 times
Summary
This phase 3 study tested whether adding the targeted drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma, a rare blood cancer. Only 3 patients took part, so the results are very early. The goal was to see if the combination could slow cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-NAЇVE MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anhui Province Cancer Hospital
Hefei, Anhui, 230009, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100143, China
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, 510180, China
-
Henan Tumor Hospital
Zhengzhou, Henan, 450008, China
-
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300052, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangxi Medical University
Guangxi, Nanning, 530021, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 3300008, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of China Medical University
Shenyang, Liaojing, 110001, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 50011, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tumor in Hunan Province
Hunan, Changsha, 410013, China
-
West China Hospital,Sichuan University
Chengdu, Sichuan, 610041, China
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
he First Affiliated Hospital of Zhengjiang University
Hangzhou, Zhejiang, 310003, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for mantle cell lymphoma, potentially delaying disease progression.
What could go wrong
This trial enrolled only 3 participants, so results are very preliminary. The combination may cause more side effects than standard therapy, and larger studies are needed to confirm benefits.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.